40 articles, transcripts, and reports
Gilead Sciences, Inc. (NASDAQ: GILD) reported total revenue of $6.6 billion for the second quarter of 2023, which was up 5% year-over-year. Net income attributable…
Gilead Sciences, Inc. (NASDAQ: GILD) reported total revenue of $6.4 billion for the first quarter of 2023, which was down 4% year-over-year. Net income attributable…
Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) has reported a sharp increase in net profit for the fourth quarter of 2022 when its revenues moved…
Gilead Sciences, Inc (NASDAQ: GILD) Q2 2022 Earnings Conference
Gilead Sciences, Inc (NASDAQ: GILD) Q1 2022 Earnings Conference
Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) reported its third-quarter 2021 earnings today after the closing bell. The revenue increased by 13% to $7.4 billion…
Gilead Sciences, Inc (NASDAQ: GILD) Q3 2021 Earnings Conference
Gilead Sciences Inc (NASDAQ: GILD) Q2 2021 earnings call dated Jul. 29, 2021. Corporate Participants: Jacquie Ross — Investor Relations Daniel O’Day — Chairman And Chief…
Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) reported its second-quarter 2021 earnings today after the closing bell. The revenue increased by 21% to $6.2 billion…
Gilead Sciences, inc (NASDAQ: GILD) Q2 2021 Earnings Conference
